(Q47974895)

7 February 2018

title

Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy (English)

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00065-9

24 December 2023

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00065-9

24 December 2023

7

Lynn C Hartmann

1 reference

7 February 2018

author name string

Gregory Lubiniecki

3

1 reference

7 February 2018

Ingegerd Hellström

8

1 reference

7 February 2018

Prema P. Peethambaram

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694661

24 December 2023

William A. Cliby

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694661

24 December 2023

Amy C. Clayton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694661

24 December 2023

Patrick C. Roche

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694661

24 December 2023

Stephen J. Iturria

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694661

24 December 2023

Scott E. Strome

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694661

24 December 2023

language of work or name

English

0 references

publication date

1 April 2003

1 reference

7 February 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0090825803000659?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00065-9

https://api.elsevier.com/content/article/PII:S0090825803000659?httpAccept=text/plain

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00065-9

24 December 2023

1 reference

7 February 2018

volume

89

1 reference

7 February 2018

issue

1

1 reference

7 February 2018

page(s)

99-104

1 reference

7 February 2018

Expression of the ErbB family of receptors in ovarian cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Amplification of HER-2/neu oncogene in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900065-9

7 January 2021

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer

1

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00065-9

24 December 2023

Identifiers

1 reference

7 February 2018

1 reference

7 February 2018